A major step in the understanding of these diseases has been achieved in 2011, with the discovery of somatic mosaic mutations in isocitrate dehydrogenase 1 or 2 genes (therefore referred as IDH mutations) in OD and MS patients with enchondromas and hemangiomas [1, 2]. Here, IDH1 is linked to myeloid sarcoma.